Home  /  Resource Library  /  Sufficient-dose Brentuximab vedotin improves prognosis in patients with classic Hodgkin lymphoma: a single-center real-world study in China

Sufficient-dose Brentuximab vedotin improves prognosis in patients with classic Hodgkin lymphoma: a single-center real-world study in China

Real world study of brentuximab vedotin for first line treatment of Hodgkin lymphoma.